A carregar...
Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies
Sorafenib is the first-line treatment of choice for advanced hepatocellular carcinoma (HCC). However, the benefits of sorafenib in HCC patients with portal vein tumour thrombosis (PVTT) remain uncertain. Until now, a total of eight comparative studies have been identified for this systematic review....
Na minha lista:
Publicado no: | Prz Gastroenterol |
---|---|
Main Authors: | , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Termedia Publishing House
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4607698/ https://ncbi.nlm.nih.gov/pubmed/26516379 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pg.2015.52470 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|